Coherus BioSciences Shares Climb 12% on FDA Approval for Cancer Treatment Loqtorzi
By Sabela Ojea
Shares of Coherus BioSciences climbed 12% to $2.96 in after-hours trading after the company said the Food and Drug Administration approved Loqtorzi to treat nasopharyngeal cancer when used with chemotherapy.
The biotechnology company said Friday that Loqtorzi is aimed at patients with metastatic nasopharyngeal cancer.
The FDA backed Loqtorzi, set to be commercially available in the U.S. in the first quarter of 2024, in combination with chemotherapy drugs cisplatin and gemcitabine.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 27, 2023 17:40 ET (21:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?